Andrianna Drosouni

Ms. Andrianna Drosouni

Democritus University of Thrace, Komotiní, Anatolikí Makedonía kai Thráki, Greece

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 November 2022 in Cancers
Verified
Journal Article
Open access
PDF file
ADAndrianna Drosouni
Andrianna Drosouni
Maria PanagopoulouMaria Panagopoulou
Maria Panagopoulou
Vassilis AidinisVassilis Aidinis
Vassilis Aidinis
Ekaterini ChatzakiEkaterini Chatzaki
Ekaterini Chatzaki
Autotaxin (ATX), the protein product of Ectonucleotide Pyrophosphatase Phosphodiesterase 2 (ENPP2), is a secreted lysophospholipase D (lysoPLD) responsible for the extracellular production of lysophosphatidic acid (LPA). ATX-LPA pathway signaling participates in several normal biological functions, but it has also been connected to cancer progression, metastasis and inflammatory processes. Significant research has established a role in breast cancer and it has been suggested as a therapeutic target and/or a clinically relevant biomarker. Recently, ENPP2 methylation was described, revealing a potential for clinical exploitation in liquid biopsy. The current review aims to gather the latest findings about aberrant signaling through ATX-LPA in breast cancer and discusses the role of ENPP2 expression and epigenetic modification, giving insights with translational value.

Verified
Journal Article
Open access
PDF file
Maria PanagopoulouMaria Panagopoulou
Maria Panagopoulou
ADAndrianna Drosouni
Andrianna Drosouni
DFDionysios Fanidis
Dionysios Fanidis
Makrina KaraglaniMakrina Karaglani
Makrina Karaglani
IBIoanna Balgkouranidou
Ioanna Balgkouranidou
Ekaterini ChatzakiEkaterini Chatzaki
Ekaterini Chatzaki
Autotaxin (ATX), encoded by the ctonucleotide pyrophosphatase/phosphodiesterase 2 (ENPP2) gene, is a key enzyme in lysophosphatidic acid (LPA) synthesis. We have recently described ENPP2 methylation profiles in health and multiple malignancies and demonstrated correlation to its aberrant expression. Here we focus on breast cancer (BrCa), analyzing in silico publicly available BrCa methylome datasets, to identify differentially methylated CpGs (DMCs) and correlate them with expression. Numerous DMCs were identified between BrCa and healthy breast tissues in the gene body and promoter-associated regions (PA). PA DMCs were upregulated in BrCa tissues in relation to normal, in metastatic BrCa in relation to primary, and in stage I BrCa in relation to normal, and this was correlated to decreased mRNA expression. The first exon DMC was also investigated in circulating cell free DNA (ccfDNA) isolated by BrCa patients; methylation was increased in BrCa in relation to ccfDNA from healthy individuals, confirming in silico results. It also differed between patient groups and was correlated to the presence of multiple metastatic sites. Our data indicate that promoter methylation of ENPP2 arrests its transcription in BrCa and introduce first exon methylation as a putative biomarker for diagnosis and monitoring which can be assessed in liquid biopsy.